PERRIGO Co plc

PRGOSEC EDGAR

Pharmaceutical Preparations(L2)CIK: 1585364

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$4.7B	$4.5B	$4.1B	$4.1B	$3.9B
Cost of Goods and Services Sold	$3.0B	$3.0B	$2.7B	$2.6B	$2.4B
Gross Profit	$1.7B	$1.5B	$1.4B	$1.5B	$1.4B
Research and Development Expense	$122.5M	$123.1M	$122.0M	$121.7M	$119.2M
Operating Expenses	$1.5B	$1.4B	$1.0B	$1.2B	$1.3B
Operating Income (Loss)	$151.9M	$78.9M	$410.4M	$265.2M	$174.7M
Other Nonoperating Income (Expense)	$10.4M	-$53.1M	-$26.7M	-$16.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$10.8B	$11.0B	$10.4B	$11.5B	$11.3B
Assets, Current	$2.5B	$2.8B	$2.7B	$3.9B	$3.1B
Cash and Cash Equivalents, at Carrying Value	—	—	—	$1.9B	$631.5M
Accounts Receivable, after Allowance for Credit Loss, Current	$642.3M	$739.6M	$697.1M	$652.9M	$593.5M
Inventory, Net	$1.1B	$1.1B	$1.2B	$1.0B	$1.1B
Liabilities	$5.3B	$6.0B	$6.2B	$5.3B	$5.8B
Liabilities, Current	$1.0B	$1.6B	$1.1B	$1.6B	$1.4B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$405.5M	$307.3M	$156.3M	$636.2M	$387.8M
Net Cash Provided by (Used in) Investing Activities	-$77.5M	-$2.0B	$1.3B	-$187.8M	-$596.1M
Net Cash Provided by (Used in) Financing Activities	-$187.2M	$421.6M	-$178.7M	-$181.1M	$1.8M
Payments to Acquire Property, Plant, and Equipment	$101.7M	$96.4M	$152.1M	$170.4M	$137.7M
Payments of Dividends	$149.7M	$142.4M	$129.6M	$123.9M	$112.4M
Payments for Repurchase of Common Stock	—	—	—	$164.2M	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)